- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
"Methylome" Could Distinguish Aggressive Triple-Negative Breast Cancer
The study identified distinct methylation patterns between the aggressive and benign forms of TNBC, which could provide an improved understanding of disease outcome.
The new study, published in Nature Communications, compares the breast cancer DNA "methylome" with that of healthy individuals. The methylome provides a new picture of the genome and shows how it is epigenetically 'decorated' with methyl groups, a process known as DNA "methylation."
The study reveals "distinct methylation patterns" in the primary biopsy breast cancer cells indicating better or worse prognosis.
Triple-negative breast cancers, which make up 15%-20% of all breast cancers, lack any of the 3 receptors (oestrogen, progesterone or HER2) that would make them responsive to targeted drugs. Overall, patients have a higher risk of disease recurrence and shorter survival than those with other breast cancers.
Read the complete press release: http://bit.ly/1D9G95L
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
